Y

Y-mAbs Therapeutics
D

YMAB

10.770
USD
0.22
(2.09%)
مغلق
حجم التداول
4,144
الربح لكل سهم
-1
العائد الربحي
-
P/E
-21
حجم السوق
482,378,349
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    C
    CRVS
    -0.31000
    (-3.64%)
    8.21000 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    G
    GLPG
    -1.130
    (-4.05%)
    26.780 USD
    I
    IMAB
    -0.06000
    (-5.50%)
    1.03000 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NVAX
    0.12000
    (1.67%)
    7.32500 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    V
    VIR
    -0.63500
    (-7.35%)
    8.01000 USD
    المزيد
الأخبار

العنوان: Y/mAbs Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.